Skip to main content
Figure 1 | Critical Care

Figure 1

From: Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective

Figure 1

The proposed mechanisms of action for rituximab, a chimeric monoclonal antibody, against the CD 20 receptor. (1) Antibody-dependent cell-mediated cytotoxicity (ADCC). Effector cells include natural killer cells and phagocytic cells such as monocytes and macrophages that express Fc receptors. (2) Complement-dependent cytotoxicity (CDC). (3) Direct effects of binding (induction of apoptosis and sensitization to other chemotherapeutic agents). (4) Antibody-dependent phagocytosis (ADP).

Back to article page

Critical Care

ISSN: 1364-8535